Mineralys Therapeutics, Inc. MLYS HTM Securities
HTM Securities at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s htm securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s HTM securities?
- Mineralys Therapeutics, Inc. (MLYS) reported HTM securities of $493.66M in Q4 2025.
- How has Mineralys Therapeutics, Inc.'s HTM securities changed year-over-year?
- Mineralys Therapeutics, Inc.'s HTM securities increased by 333.3% year-over-year, from $113.92M to $493.66M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s HTM securities?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s HTM securities has grown at a 180.3% compound annual growth rate (CAGR), from $22.41M to $493.66M.
- What does HTM securities mean?
- Debt securities the company intends and is able to hold until maturity, carried at amortized cost rather than fair value.